[Intraperitoneal lymphatic chemotherapy for colonic cancer]

Area of Science:

• Oncology
• Surgical Oncology
• Pharmacology

Background:

• Colonic carcinoma poses a significant risk of abdominal lymphatic metastasis.
• Effective management of lymphatic spread is crucial after radical resection for colonic cancer.

Purpose of the Study:

• To assess the efficacy of intraperitoneal lymphatic chemotherapy using carboplatin and sandostatin.
• To evaluate its impact on colonic carcinoma and abdominal lymphatic metastasis after surgery.

Main Methods:

• A comparative study divided colonic cancer patients into two groups: lymphatic chemotherapy and control.
• The lymphatic chemotherapy group received intraperitoneal carboplatin and subcutaneous sandostatin.
• Platinum levels in lymph nodes were monitored, and retroperitoneal lymphatic metastasis was assessed via CT scan post-operation.

Main Results:

• Significantly higher platinum levels were observed in abdominal lymph nodes of the lymphatic chemotherapy group.
• The rate of retroperitoneal lymphatic metastasis was significantly lower in the lymphatic chemotherapy group compared to the control.
• No significant difference in platinum levels was found in the portal vein or between metastatic and non-metastatic lymph nodes.

Conclusions:

• Intraperitoneal carboplatin and sandostatin effectively increase platinum concentration in abdominal lymph nodes.
• This combination therapy reduces abdominal lymphatic metastasis following radical resection of colonic cancer.
• Intraperitoneal lymphatic chemotherapy is a promising strategy for managing lymphatic spread in colonic cancer.